We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Criticizes FDA's Proposed Labeling for Advair, Serevent
GSK Criticizes FDA's Proposed Labeling for Advair, Serevent
November 23, 2005
Labeling changes proposed by the FDA to three lucrative asthma drugs are inconsistent with established treatment guidelines and could put patients at increased risk, according to GlaxoSmithKline (GSK), which manufactures two of the medicines.